CHIR-99021 Projects You Could Perform On Your Own

001) (Fig.?1A); a prognostic difference appeared within the good-risk group (n= 47; HR, 3.56; P= 0.012) and the intermediate risk group (n= 39; HR, 2.42; P= 0.044), with a similar, statistically non-significant trend in the poor risk group (n= 20; HR, 2.80; P= 0.18) (Fig.?1B). Only seven patients had an abnormal C-reactive protein (��8?ng/mL) and they had a median OS of 5.5 months (95% CI, 4.2�C13.7), which was significantly worse than men who had normal C-reactive protein (HR, 4.20; 95% CI, 1.66�C10.63; P= 0.002) (Fig.?1C). Patients who had C-reactive protein measured had a lower probablility of having ��2 metastatic sites, significant pain, ECOG 1 or 2 performance status, previous PSA progression, disease stage 3 or 4 and PSA doubling time http://www.selleck.cn/products/wortmannin.html patients with C-reactive protein measured http://www.selleckchem.com/products/CHIR-99021.html (see Supporting information, Table?S1), those with C-reactive protein above the median had a higher probablility of poor performance status (ECOG 1�C2), pain, bone scan progression, no previous radical prostatectomy and high Gleason sum (8�C10), and also higher median PSA and alkaline phosphatase levels and lower haemoglobin and albumin levels. Men with C-reactive protein levels above the median had a higher probablility of belonging to the poor risk classification, although they had a lower probablility of visceral/liver metastases and a higher probablility of node-only metastatic disease. Despite the fact that these patients were different from the population as a whole, the prognostic ability of the risk grouping, the PCWG-2 classifier and nomograms on OS and PFS, as measured by the HRs, were generally similar within this smaller cohort (Table?2). As a continuous value on the logarithmic scale, C-reactive protein remained statistically significantly prognostic for OS after adjusting for the estimates using the Armstrong (P= 0.002), Halabi (P http://www.selleckchem.com/products/LY294002.html Alternatively, the nomogram estimators and the risk group or PCWG-2 classification were not statistically significant after adjusting for log(C-reactive protein). A sensitivity analysis was performed excluding all patients with abnormally high C-reactive protein levels (��8?ng/mL) with similar results being obtained (data not shown). Discrimination ability (concordance probability) using log(C-reactive protein) as an univariate prognostic factor was 0.65 for both OS and PFS. Adding the nomogram estimates to log(C-reactive protein) did not substantially increase the discrimination ability over log(C-reactive protein) alone.